SCHEMBL21752371

SCHEMBL21752371

Cc1c(F)cccc1NC(=O)C=NO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.52
HPGD P15428 1/20 0.52
MAPK1 P28482 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP1A2 P05177 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ALDH1A1 P00352 4/20 0.47
GAA P10253 1/20 0.47
THRB P10828 1/20 0.44
TP53 P04637 1/20 0.42
MMP1 P03956 2/20 0.41
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
EGFR P00533 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CXCR2 P25025 3/20 0.39
POLB P06746 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30636380 1.00 SMN1; SMN2 (0.52) SMN1; SMN2HPGDMAPK1MEN1KMT2A
SCHEMBL21752369 1.00 SMN1; SMN2 (0.52) SMN1; SMN2HPGDMAPK1MEN1KMT2A
SCHEMBL29889921 1.00 SMN1; SMN2 (0.52) SMN1; SMN2HPGDMAPK1MEN1KMT2A
SCHEMBL26933129 1.00 SMN1; SMN2 (0.52) SMN1; SMN2HPGDMAPK1MEN1KMT2A
SCHEMBL13909387 0.84 HPGD (0.55) HPGDMAPK1CYP1A2NPSR1ALDH1A1
SCHEMBL3954474 0.84 MEN1 (0.51) SMN1; SMN2HPGDMAPK1MEN1KMT2A
SCHEMBL31355600 0.84 MEN1 (0.51) SMN1; SMN2HPGDMAPK1MEN1KMT2A
SCHEMBL4189803 0.84 HPGD (0.55) HPGDMAPK1CYP1A2NPSR1ALDH1A1
SCHEMBL2898601 0.84 HPGD (0.55) HPGDMAPK1CYP1A2NPSR1ALDH1A1
SCHEMBL12489800 0.84 MEN1 (0.51) SMN1; SMN2HPGDMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof BAUSCH + LOMB IRELAND LIMITED (IE) 2025-10-07 US disclosed
EP-3841086-B1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2025-04-23 EP disclosed
US-20240308965-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2024-09-19 US disclosed
WO-2024129896-A1 INHIBITORS OF PROCASPASE-6 ACTIVATION AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 WO disclosed
EP-4313951-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF Novartis AG (CH) 2024-02-07 EP disclosed
US-11845730-B2 1,3-substituted cyclobutyl derivatives and uses thereof CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2023-12-19 US disclosed
CN-117062804-A 1, 3-substituted cyclobutyl derivatives and their use 诺华股份有限公司 2023-11-14 CN disclosed
US-20230022157-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2023-01-26 US disclosed
US-20220324811-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2022-10-13 US disclosed
WO-2022201097-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2022-09-29 WO disclosed
CN-114671827-A O-benzoylsulfimide derivative and its application 杭州百新生物医药科技有限公司 2022-06-28 CN disclosed
EP-3841086-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS Achillion Pharmaceuticals, Inc. (US) 2021-06-30 EP disclosed
CN-111606928-A Azacyclodiketone compound and preparation method thereof 维清生物科技(上海)有限公司 2020-09-01 CN disclosed
WO-2020041301-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845730-B2 1,3-substituted cyclobutyl derivatives and uses thereof TRPV1, TRPV3, TRPV2 SMN1; SMN2 3896/4885HPGD 570/4885MAPK1 2093/4885
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof TRPV1, TRPV3, TRPV2 SMN1; SMN2 3896/4885HPGD 570/4885MAPK1 2093/4885
US-20220324811-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF TRPV1, TRPV3, TRPV2 SMN1; SMN2 3896/4885HPGD 570/4885MAPK1 2093/4885
US-20240308965-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF TRPV1, TRPV3, TRPV2 SMN1; SMN2 3896/4885HPGD 570/4885MAPK1 2093/4885
US-20230022157-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS CFD, CFH, TFPI SMN1; SMN2 4033/4885HPGD 937/4885MAPK1 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.